Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
---|---|---|---|---|---|
Novartis | 1549 | 997 | 100.0% | 343 | major |
GlaxoSmithKline | 1199 | 727 | 100.0% | 379 | major |
Pfizer | 916 | 589 | 99.3% | 233 | major |
Merck Sharp & Dohme (MSD) | 870 | 523 | 100.0% | 212 | major |
Roche | 807 | 429 | 98.8% | 202 | major |
Astrazeneca | 749 | 425 | 97.9% | 147 | major |
Sanofi S.A. | 769 | 403 | 100.0% | 297 | major |
Johnson & Johnson | 593 | 342 | 99.4% | 155 | major |
Eli Lilly | 492 | 323 | 99.1% | 86 | major |
Boehringer Ingelheim | 400 | 315 | 100.0% | 53 | major |
Medical University of Vienna | 463 | 291 | 93.5% | 37 | major |
Bayer | 347 | 257 | 100.0% | 59 | major |
Bristol-Myers Squibb | 412 | 224 | 100.0% | 107 | major |
KU Leuven | 279 | 209 | 96.2% | 13 | major |
Amgen Inc | 308 | 204 | 100.0% | 65 | major |
Novo Nordisk | 284 | 191 | 100.0% | 47 | major |
Gilead Sciences Inc | 269 | 172 | 100.0% | 70 | major |
Charité-Universitätsmedizin Berlin | 214 | 170 | 100.0% | 8 | major |
Rigshospitalet | 269 | 161 | 59.0% | 26 | major |
Takeda | 263 | 156 | 100.0% | 70 | major |
Aarhus University | 224 | 141 | 70.2% | 16 | major |
Abbvie | 271 | 140 | 99.3% | 72 | major |
Merck KGaA | 179 | 127 | 100.0% | 32 | major |
UCB | 239 | 123 | 100.0% | 95 | major |
Servier Laboratories | 154 | 117 | 100.0% | 21 | major |
Astellas | 159 | 110 | 100.0% | 32 | major |
Allergan | 147 | 106 | 99.1% | 32 | major |
Imperial College London | 145 | 103 | 100.0% | 3 | major |
Medical University of Graz | 140 | 100 | 90.0% | 9 | major |
Pierre Fabre S.A. | 122 | 99 | 99.0% | 9 | major |
Radboud University Medical Centre | 274 | 98 | 84.7% | 62 | major |
Biogen | 140 | 92 | 96.7% | 30 | major |
University College London | 163 | 90 | 98.9% | 9 | major |
Amsterdam UMC | 418 | 87 | 34.5% | 55 | major |
No Sponsor Name Given | 253 | 87 | 65.5% | 27 | major |
Ghent University | 158 | 87 | 82.8% | 49 | major |
Abbott | 109 | 87 | 96.6% | 18 | major |
University of Oxford | 146 | 86 | 100.0% | 0 | major |
Chiesi Farmaceutici S.p.A | 117 | 79 | 100.0% | 24 | major |
Shire | 115 | 79 | 100.0% | 23 | major |
Teva | 100 | 78 | 98.7% | 15 | major |
Odense University Hospital | 120 | 77 | 92.2% | 16 | major |
Celgene | 150 | 76 | 98.7% | 41 | major |
H. Lundbeck A/S | 95 | 75 | 98.7% | 14 | major |
King’s College London | 108 | 73 | 98.6% | 6 | major |
Hospitals of Paris (AP-HP) | 403 | 70 | 24.3% | 61 | major |
Eisai Inc. | 131 | 69 | 100.0% | 46 | major |
University of Dundee | 74 | 69 | 100.0% | 1 | major |
European Organisation for the Research and Treatment of Cancer (EORTC) | 111 | 66 | 98.5% | 24 | major |
Herlev and Gentofte Hospital | 105 | 66 | 69.7% | 13 | major |
Novartis Vaccines | 132 | 65 | 100.0% | 63 | major |
Actelion Pharmaceuticals Ltd | 99 | 65 | 100.0% | 27 | major |
Ipsen | 105 | 64 | 100.0% | 22 | major |
Vertex Pharmaceuticals, Inc. | 117 | 62 | 100.0% | 38 | major |
Genentech | 80 | 61 | 100.0% | 10 | major |
IRCCS Ospedale San Raffaele | 166 | 60 | 91.7% | 15 | major |
Menarini Group | 72 | 58 | 100.0% | 7 | major |
Otsuka | 84 | 57 | 100.0% | 19 | major |
University of Nottingham | 63 | 57 | 100.0% | 2 | major |
Innsbruck Medical University | 82 | 56 | 91.1% | 6 | major |
LEO Pharma A/S | 70 | 56 | 100.0% | 11 | major |
Galderma R&D | 69 | 56 | 98.2% | 7 | major |
The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 56 | 94.6% | 1 | major |
University of Cologne | 82 | 55 | 98.2% | 1 | major |
Ferring Pharmaceuticals | 60 | 54 | 100.0% | 4 | major |
University of Birmingham | 118 | 53 | 100.0% | 8 | major |
Manchester University NHS Foundation Trust | 63 | 53 | 100.0% | 1 | major |
CSL Behring | 89 | 52 | 100.0% | 30 | major |
University of Munich (Ludwig-Maximilians) | 85 | 52 | 71.2% | 5 | major |
University of Leeds | 72 | 52 | 98.1% | 0 | major |
Bispebjerg Hospital | 71 | 52 | 55.8% | 7 | major |
Almirall S.A. | 62 | 51 | 100.0% | 8 | major |
Guy's and St Thomas' NHS Foundation Trust | 82 | 50 | 96.0% | 3 | major |
Daiichi Sankyo | 86 | 49 | 100.0% | 21 | major |
University Hospital Tübingen | 72 | 49 | 83.7% | 3 | major |
Baxter | 64 | 49 | 95.9% | 8 | major |
Hannover Medical School | 58 | 49 | 93.9% | 3 | major |
Helsinki University | 130 | 46 | 28.3% | 20 | major |
Technical University of Munich | 72 | 46 | 100.0% | 14 | major |
Belfast Health and Social Care Trust | 55 | 46 | 97.8% | 0 | major |
Mundipharma | 55 | 46 | 93.5% | 4 | major |
Karolinska Institutet | 90 | 45 | 82.2% | 10 | major |
University Hospitals of Leicester NHS Trust | 56 | 45 | 97.8% | 5 | major |
Alcon | 76 | 44 | 100.0% | 31 | major |
ACCORD (University of Edinburgh & NHS Lothian) | 66 | 44 | 97.7% | 2 | major |
Barts Health NHS Trust | 51 | 44 | 100.0% | 4 | major |
Queen Mary University of London | 65 | 43 | 100.0% | 4 | major |
Heidelberg University Hospital | 68 | 42 | 88.1% | 3 | major |
Cambridge University Hospitals NHS Foundation Trust | 50 | 42 | 95.2% | 0 | major |
King's College Hospital NHS Foundation Trust | 53 | 41 | 97.6% | 2 | major |
NHS Greater Glasgow and Clyde | 71 | 40 | 100.0% | 2 | major |
Alexion Pharmaceuticals, Inc | 85 | 39 | 97.4% | 32 | major |
Regeneron Pharmaceuticals Inc. | 94 | 38 | 100.0% | 33 | major |
Hvidovre Hospital | 57 | 38 | 47.4% | 8 | major |
University Erlangen-Nuremberg | 64 | 37 | 81.1% | 5 | major |
Johannes Gutenberg University of Mainz | 53 | 36 | 72.2% | 6 | major |
Karolinska University Hospital | 140 | 35 | 31.4% | 16 | major |
Octapharma AG | 54 | 34 | 100.0% | 14 | major |
Mario Negri Institute | 63 | 33 | 97.0% | 15 | major |
Oslo University Hospital | 125 | 32 | 43.8% | 14 | major |